Oruka Therapeutics, Financials
| ORKA Stock | 20.26 1.57 8.40% |
EPS Estimate Current Year (1.64) |
Oruka |
Understanding current and past Oruka Therapeutics, Financials, including the trends in assets, liabilities, equity and income are directly related to making proper and timely investing decisions. All of Oruka Therapeutics,'s financial statements are interrelated, with each one affecting the others. For example, an increase in Oruka Therapeutics,'s assets may result in an increase in income on the income statement.
Please note, the presentation of Oruka Therapeutics,'s financial position, as portrayed in its financial statements, is often influenced by management's estimates, judgments, and sometimes even manipulations. In the best case, Oruka Therapeutics,'s management is honest, while the outside auditors are strict and uncompromising. Please utilize our Beneish M Score to check the likelihood of Oruka Therapeutics,'s management manipulating its earnings.
Oruka Therapeutics, Stock Summary
Oruka Therapeutics, competes with Ikena Oncology, Eliem Therapeutics, HCW Biologics, RenovoRx, and Tempest Therapeutics. Oruka Therapeutics, is entity of United States. It is traded as Stock on NASDAQ exchange.Specialization | Health Care, Pharmaceuticals, Biotechnology & Life Sciences |
| Instrument | USA Stock View All |
| Exchange | NASDAQ Exchange |
| CUSIP | 00211Y506 00211Y209 00211Y407 687604108 00211Y100 67072M301 449163302 67072M103 |
| Older Symbol | ABIO |
| Sector | Biotechnology |
| Industry | Health Care |
| Benchmark | Dow Jones Industrial |
Oruka Therapeutics, Key Financial Ratios
Oruka Financial Ratios Relationships
Comparative valuation techniques use various fundamental indicators to help in determining Oruka Therapeutics,'s current stock value. Our valuation model uses many indicators to compare Oruka Therapeutics, value to that of its competitors to determine the firm's financial worth. You can analyze the relationship between different fundamental ratios across Oruka Therapeutics, competition to find correlations between indicators driving Oruka Therapeutics,'s intrinsic value. More Info.Oruka Therapeutics, is rated top company in current valuation category among its peers. It is rated below average in shares outstanding category among its peers . The ratio of Current Valuation to Shares Outstanding for Oruka Therapeutics, is about 899.11 . The reason why the comparable model can be used in almost all circumstances is due to the vast number of multiples that can be utilized, such as the price-to-earnings (P/E), price-to-book (P/B), price-to-sales (P/S), price-to-cash flow (P/CF), and many others. The P/E ratio is the most commonly used of these ratios because it focuses on the Oruka Therapeutics,'s earnings, one of the primary drivers of an investment's value.Oruka Therapeutics, Systematic Risk
Oruka Therapeutics,'s systematic risk plays a vital role in portfolio allocation when considering its stock to be added to a well-diversified portfolio. Oruka Therapeutics, volatility which cannot be eliminated through diversification, requires returns over the risk-free rate. Over the long run, a well-diversified portfolio provides returns that match its exposure to systematic risk. In this case, investors face a trade-off between expected returns and systematic risk and, therefore, can only reduce a portfolio's exposure to systematic risk by sacrificing expected returns on the portfolio.
Incorrect Input. Please change your parameters or increase the time horizon required for running this function. The output start index for this execution was zero with a total number of output elements of zero. The Beta measures systematic risk based on how returns on Oruka Therapeutics, correlated with the market. If Beta is less than 0 Oruka Therapeutics, generally moves in the opposite direction as compared to the market. If Oruka Therapeutics, Beta is about zero movement of price series is uncorrelated with the movement of the benchmark. if Beta is between zero and one Oruka Therapeutics, is generally moves in the same direction as, but less than the movement of the market. For Beta = 1 movement of Oruka Therapeutics, is generally in the same direction as the market. If Beta > 1 Oruka Therapeutics, moves generally in the same direction as, but more than the movement of the benchmark.
Oruka Therapeutics, November 28, 2024 Opportunity Range
Along with financial statement analysis, the daily predictive indicators of Oruka Therapeutics, help investors to analyze its daily demand and supply, volume, patterns, and price swings to determine the real value of Oruka Therapeutics,. We use our internally-developed statistical techniques to arrive at the intrinsic value of Oruka Therapeutics, based on widely used predictive technical indicators. In general, we focus on analyzing Oruka Stock price patterns and their correlations with different microeconomic environment and drivers. We also apply predictive analytics to build Oruka Therapeutics,'s daily price indicators and compare them against related drivers.
| Information Ratio | (0.03) | |||
| Maximum Drawdown | 46.36 | |||
| Value At Risk | (11.46) | |||
| Potential Upside | 8.4 |
Complementary Tools for Oruka Stock analysis
When running Oruka Therapeutics,'s price analysis, check to measure Oruka Therapeutics,'s market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Oruka Therapeutics, is operating at the current time. Most of Oruka Therapeutics,'s value examination focuses on studying past and present price action to predict the probability of Oruka Therapeutics,'s future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Oruka Therapeutics,'s price. Additionally, you may evaluate how the addition of Oruka Therapeutics, to your portfolios can decrease your overall portfolio volatility.
| Technical Analysis Check basic technical indicators and analysis based on most latest market data | |
| Efficient Frontier Plot and analyze your portfolio and positions against risk-return landscape of the market. | |
| Correlation Analysis Reduce portfolio risk simply by holding instruments which are not perfectly correlated | |
| ETF Categories List of ETF categories grouped based on various criteria, such as the investment strategy or type of investments | |
| Money Managers Screen money managers from public funds and ETFs managed around the world | |
| Portfolio Volatility Check portfolio volatility and analyze historical return density to properly model market risk |